|
Radiosensitivity of HPV-related Tumors: Towards a Genomic Approach
RECRUITINGSponsored by European Institute of Oncology
Actively Recruiting
SponsorEuropean Institute of Oncology
Started2023-04-14
Est. completion2024-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06321627
Summary
The purpose of this study is therefore to analyze the genomic profiles of prognosis and radiosensitivity of Human Papilloma Virus (HPV) related tumors from different body sites (oropharynx, uterine cervix, and anus), considering them as a unified entity regardless of the site of origin within the body.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Adult patients (\>18 years old) * Diagnosis of HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus * Curative intent radiation therapy (exclusive, post-operative, with or without chemotherapy) * Availability of pre-radiation therapy biopsy sample * No diagnosis of solid neoplasms and/or hematologic malignancies in the previous 5 years * Possibility of retrospective and prospective data collection and anonymous submission to the referring center of clinical data related to the patient, pathology, and treatment characteristics (including radiation treatment plan in RT.dose format) * Ability to obtain written informed consent for the use of data anonymously for research purposes Exclusion Criteria: * Patients undergoing surgical treatment * Patients with local and/or locoregional recurrence * Patients with synchronous distant metastases at diagnosis * Patients previously treated with oncologic therapies for tumors of the same anatomical site
Conditions2
CancerHPV-Related Carcinoma
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorEuropean Institute of Oncology
Started2023-04-14
Est. completion2024-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06321627